23 results about "BCG vaccine" patented technology

The invention belongs to the technical field of biological medicine, and relates to pharmaceutical application of an oxidative phosphorylation inhibitor, in particular to application of the oxidative phosphorylation inhibitor in preparation of an immunomodulatory drug, and the immunomodulatory drug has the advantages that the function damage of newborn myeloid-derived suppressor cells caused by antagonism BCG (bacillus calmette guerin) vaccination is inhibited, and the immunomodulatory effect is improved. The compound is used for preventing or treating neonatal immune-related diseases caused by bacillus calmette guerin vaccine inoculation. The invention finds that the BCG can cause damage to the immunosuppression function of the MDSC of the suckling mouse through up-regulation oxidative phosphorylation, and the negative effect caused by inoculation of the BCG can be reversed by using the OXPHOS inhibitor, so that the immunosuppression function of the MDSC of the suckling mouse is successfully recovered in an in-vivo and in-vitro model, and the immune-related adverse reaction caused by inoculation of the BCG is expected to be improved.

The application provides a self-driven BCG-nanoparticle complex and a preparation method thereof, and belongs to the fields of biological medicine and nanomaterials. The complex is a composite of BCG and cerium oxide nanoparticles with urease activity, the cerium oxide nanoparticles are coupled to the surface of the BCG in an asymmetric distribution through modified polyethyleneimine, and specifically, the surface of the BCG is connected to several modified polyethyleneimine derivatives through chemical bonds and electrostatic adsorption, and the polyethyleneimine derivatives wrap the cerium oxide nanoparticles through electrostatic adsorption. The complex can be self-driven by using the gas release and ion concentration change caused by the catalytic decomposition of urea in the environment, significantly enhances the adhesion and retention of BCG on the bladder wall, effectively overcomes the defects of low delivery efficiency and insufficient immune activation of traditional BCG therapy, simultaneously improves the tumor immune microenvironment, and can be used for preparing high-efficiency and low-toxicity bladder cancer treatment drugs.

The invention relates to the field of vaccines, in particular to application of a bacillus calmette-guerin vaccine and a complete freund's adjuvant in preparation of tuberculosis prevention vaccines. The invention provides a novel inoculation strategy of subcutaneous combined inoculation of the bacillus calmette guerin vaccine and the complete freund's adjuvant, the safety consistent with that of the existing tuberculosis prevention vaccine in the clinical stage is achieved, and the immune protection effect higher than that of the existing tuberculosis prevention vaccine in the clinical stage and the preclinical research stage is achieved. The compound is expected to be used as a novel tuberculosis vaccine for preventing tuberculosis.

The present disclosure relates to a BCG based therapeutic agent using a BCG strain that overexpresses the STING agonist, c-di-AMP. This BCG strain, called BCG-disA-OE, enhances the elevated trained immunity of macrophages and promotes early anti-viral Type I interferon responses in a subject, providing protection against viral infections such as primary respiratory infections and SARS-CoV-2 infection.

The invention relates to the technical field of biology, in particular to a protective monoclonal antibody targeting BCG (bacillus calmette guerin) BCG3965 as well as a preparation method and application of the protective monoclonal antibody. The antibody or an antigen binding fragment comprises a CDR sequence selected from at least one of the following sequences or a sequence with one amino acid substituted, deleted or increased: a heavy chain variable region CDR sequence: SEQ ID NO: 3-5; and the light chain variable region CDR sequences are as shown in SEQ ID NO: 7-9. The monoclonal antibody 5F10 shows efficient antituberculous activity in vivo and in vitro through specific targeting of BCG3965 protein on the surface of mycobacterium tuberculosis, mainly including the aspects of remarkably enhancing the phagocytosis of macrophages on tubercle bacillus, inhibiting tubercle bacillus growth and the like, and in addition, the monoclonal antibody 5F10 is clear in sequence and structure, easy to develop and modify, and capable of being used for preparing antituberculous drugs for treating mycobacterium tuberculosis. The monoclonal antibody 5F10 disclosed by the invention has the advantages that the monoclonal antibody 5F10 is not easy to induce pathogens to generate drug resistance by an immune-mediated treatment mechanism, and the monoclonal antibody 5F10 is applied to prevention and treatment of tuberculosis, not only provides a new choice for treatment of tuberculosis, but also provides an important technical basis for response of drug-resistant strains, development of diagnostic reagents, vaccine development and the like, and is wide in application prospect.

The invention relates, in part, to a method for the prophylactic treatment of a coronavirus infection in a human adult subject comprising administering at least two doses of a Bacillus Calmette-Guerin (BCG) vaccine to the subject, wherein the subject is a type I diabetic.

The invention provides a self-driven bacillus calmette-guerin vaccine-nano enzyme compound and a preparation method thereof, and belongs to the field of biological medicines and nano materials. The compound is a compound of bacillus calmette-guerin and cerium oxide nanoparticles with urease activity, the cerium oxide nanoparticles are coupled to the surface of the bacillus calmette-guerin through modified polyethyleneimine and are asymmetrically distributed, specifically, the surface of the bacillus calmette-guerin is connected with a plurality of modified polyethyleneimine derivatives through chemical bonds and an electrostatic adsorption effect, and the modified polyethyleneimine derivatives are coupled to the surface of the bacillus calmette-guerin. The cerium oxide nano particles are wrapped by the polyethyleneimine derivative through an electrostatic adsorption effect. The compound provided by the invention can realize self-driving by utilizing gas release and ion concentration change caused by urea catalytic decomposition in an environment, remarkably enhances the adhesion and retention of BCG on a bladder wall, effectively overcomes the defects of low delivery efficiency and insufficient immune activation of a traditional BCG therapy, improves a tumor immune microenvironment, and improves the tumor immune activity. The compound can be used for preparing high-efficiency and low-toxicity bladder cancer treatment medicines.

For the purpose of determination for the selection of intravesical BCG instillation therapy, the present invention comprises measuring 2-ethylhydracrylic acid-2, arabinonic acid-2, carnitine, lauric acid, myristic acid, octanoylcarnitine, paraxanthine, S-methylcysteine, S-methylcysteine-S-oxide, SDMA, theobromine, indole-3-acetic acid, pentanoic acid, 1-methyl-4-imidazoleacetic acid, ADMA, alanine, argininosuccinic acid, choline, citrulline, creatinine, guanidoacetic acid, lysine, methionine sulfoxide, myristic acid, N-(1-deoxy-1-fructosyl)leucine, N-acetylneuraminic acid, N6,N6,N6-trimethyllysine, propionylcarnitine, threonine, gamma-glutamyl-glycine, gamma-glutamyl-tyrosine, and gamma-glutamyl-valine in blood, serum, or plasma.

The invention relates to an immunogenic formulation that confers protection against respiratory viruses which comprises an attenuated recombinant strain of Bacillus Calmette and Guerin (BCG), in a concentration of between 104 109 bacteria, which expresses at least one immunogenic protein or fragment of the respiratory syncytial virus (RSV). And to the use of this immunogenic formulation to prepare a vaccine to prevent, treat, or attenuate infections of respiratory viruses, especially hRSV and / or hMPV.

This disclosure relates to methods for treating diseases and / or conditions (including long COVID) associated with Covid-19 infection, the methods comprising administering a COX-2 inhibitor, an antiviral compound, and one or more additional active ingredients, such as a combination of nematvir and ritonavir, monorapvir, a BCG vaccine, or ivermectin.

The Mtb protein Rv2140c, specific peptide epitopes derived, and polynucleotide sequences encoding such polypeptides are disclosed herein as a useful TB antigen for generating a protective immune response to development of tuberculosis. In some embodiments the Rv2140c polypeptide or polynucleotide is formulated as a vaccine. In some embodiments the Rv2140c vaccine is administered to a naïve recipient. In some embodiments the Rv2140c vaccine is administered as a booster to a previously vaccinated to exposed individual. In some embodiments the previous vaccination is a BCG vaccination.

The application relates to immunoconjugates for use in a method of treating bladder cancer in a human patient, wherein the method comprises administering the immunoconjugate to the patient, wherein the immunoconjugate comprises: (i) an antibody that binds to PD-1; and (ii) a mutant IL-2 polypeptide comprising the amino acid substitutions F42A, Y45A and L72G. The immunoconjugates are capable of binding in cis to PD-1 and stimulating IL-2 signalling on the same cell, providing selective IL-2 receptor signalling on PD-1 positive T cells relative to the PD-1 negative T cells. The application also relates to the use of the immunoconjugates in combination with immunotherapeutic agent, which is bacterial strain or an oncolytic virus, such as the BCG vaccine.

This invention relates to the field of tumor vaccines, specifically to an anti-tumor vaccine, its preparation method, and its application. The invention prepares an anti-tumor vaccine, BCG-CW@LNT, by mixing cell walls extracted from BCG vaccine as an immune adjuvant with LNT cells obtained from tumor cells through rapid freeze-thaw cycles in liquid nitrogen. This vaccine utilizes these "therapeutic dead cells" to induce a broad antigen response throughout the entire cell, mimicking the natural presentation of antigens in the tumor microenvironment, thereby enhancing anti-cancer immunity. In bladder cancer and lung cancer models, BCG-CW@LNT demonstrated good anti-tumor therapeutic effects. Furthermore, due to the presence of memory T cells, it exhibits a long-term memory effect, providing long-term anti-tumor and preventative effects, effectively preventing tumor recurrence and offering a novel option for tumor treatment.

The application provides a serum antibody IgG specific recognition vaccine strain antigen spectrum and a screening method and application thereof, serum of an experimental group and a control group is screened in advance, serum samples of latent infection human groups without producing tuberculosis antibodies and containing anti-tubercle bacillus protein antibodies are removed, then the screened serum antibodies are subjected to biomimetic affinity and affinity chromatography, high-purity serum antibody IgG is obtained, the high-purity serum antibody IgG after biomimetic affinity and affinity chromatography is covalently coupled to a solid-phase carrier material, and different types of serum antibody columns are prepared; after affinity chromatography of different types of serum antibody columns and BCG total protein, Gly-HCl (pH1.5-3.0) can only elute the combined BCG protein on the columns but not high-abundance serum antibody IgG, LC-MS / MS can detect low, medium and high concentrations of BCG protein, and a BCG antigen spectrum specifically combined with serum antibodies of tuberculosis patients is constructed, which is used for tuberculosis protein vaccine development and / or serum protein marker library research.

Disclosed are compositions and methods for the treatment of cancer through administration of gemcitabine, tumor infiltrating lymphocytes and bacillus Calmette-Buerin (BCG) as well as models for predicting responsiveness to said treatment.

To provide a method capable of determining the selection of a BCG intravesical injection therapy and total cystectomy with less burden on patients.SOLUTION: 2-ethylhydracrylic acid-2, arabinonic acid-2, carnitines, lauric acids, myristic acids, octanoylcarnitines, paraxanthine, S-methylcysteine, S-methylcysteine-S-oxide, SDMA, theobromine, indole-3-acetic acids, pentanoic acids, 1-methyl-4-imidazoleacetic acids, ADMA, alanine, argininosuccinic acids, choline, citrulline, creatinine, guanidoacetic acids, lysine, methionine sulfoxide, myristic acids, N - (1-deoxy-1-fructosyl) leucine, N-acetylneuraminic acids, N6, N6, N6 trimethyllysine, propionylcarnitines, threonine, gamma-glutamyl-glycine, gamma-glutamyl-tyrosine, the method comprises measuring gamma-glutamyl-valine.SELECTED DRAWING: Figure 1

The invention provides a genetically modified tubercle bacillus strain as well as a preparation method and application thereof, the strain is tubercle bacillus obtained by knocking out virulence-related genes by adopting a genetic engineering method and simultaneously supplementing and enhancing immunogenicity antigen genes, and can be used for preparing attenuated live vaccines. The attenuated live vaccine prepared by using the strain has lower adverse reaction rate and stronger immunogenicity, and can be used for replacing a bacillus calmette guerin vaccine or a booster vaccine. Moreover, the DTH reaction caused by vaccination or infection can be identified through TBST (based on Mycobacterium tuberculosis antigen skin test) by using the vaccine prepared by the strain, and the strain has important application in tuberculosis vaccine production.

The invention discloses a method for detecting latent infection of tubercle bacillus, and belongs to the field of tuberculosis detection. According to the method, detection of latent infection of tubercle bacillus is completed through the steps of sample collection, sample treatment, marker detection, data analysis, result judgment and the like. According to the invention, mycobacterium tuberculosis specific extracellular RNA (exoRNA) is selected as a novel biomarker. Compared with the traditional protein or DNA marker, the exoRNA has higher sensitivity and specificity, and can reflect the existence and activity state of the pathogen earlier and more accurately. The application of the marker effectively reduces the risk of cross reaction caused by bacillus calmette guerin vaccine inoculation or nontuberculous mycobacterium infection, thereby improving the reliability of the detection result. According to the invention, a high-throughput sequencing technology and an artificial intelligence algorithm are combined, and an intelligent diagnosis model is constructed. The method not only can realize qualitative judgment of LTBI, but also can finely distinguish infection states by analyzing the combination and expression profile of the exoRNA markers.

This invention provides an antigenic polypeptide for anti-tumor immune regulation, a screening method thereof, and its application. The antigenic polypeptide is derived from BCG, and its amino acid sequence is shown in SEQ ID NO. 1-8. The screening method combines immunomass spectrometry detection with antigenicity prediction. The antigenic polypeptide can activate CD8. + T cells regulate the tumor immune microenvironment and induce intratumoral CD8. + The increase in T and DC2.4 cells, coupled with the enhanced induction effect of the peptide delivered via iodized oil, provides a strong basis for the screening method of this invention. This invention provides technical support for the development of novel BCG antitumor agents, enriches the application of BCG in antitumor therapy, and offers insights for the development of tumor immunotherapy materials.

A multivalent tuberculosis vaccine comprises one or both Mycobacterium tuberculosis transmembrane copper transporters CtpV (SEQ ID NO: 1) and MctB (SEQ ID NO: 2) reconstituted into proteoliposomes at a protein-to-lipid ratio of 1:15 to 1:40 (w / w). The proteoliposomes, optionally combined in a 1:1 to 3:1 ratio and formulated with CpG ODN 2395, 7909, or 1018, are encapsulated in ZIF-8 or multivariate Mn-ZIF (15-50 % Mn) to yield shelf- stable nanoparticles. Intranasal or pulmonary administration elicits robust Thl-biased immunity, polyfunctional CD4+ T-cells, and IgG2a-dominant antibodies, achieving >0.3 login CPU reduction in lungs versus saline and superior Th1 / Th2 balance versus BCG in murine aerosol challenge models. A metalloimmunological adjuvant comprising CDA-loaded Mn-ZIF synergistically activates cGAS-STING, enhancing dendritic cell maturation and protective efficacy when combined with tuberculosis antigens. Kits and methods for vaccination and manufacture are provided.

The invention relates to the field of animal immunity, in particular to a method for improving antigen immunogenicity. According to the invention, a high-homology antigen and a bacillus calmette-guerin vaccine are subjected to covalent coupling to form an antigen-bacillus calmette-guerin vaccine compound, and the antigen-bacillus calmette-guerin vaccine compound is immunized in an intravenous injection manner. The method is simple, fusion expression of protein or polypeptide and other proteins or coupling of a special costimulatory sequence is not needed, and the coupling method and the injection way are mature technologies in the industry. By referring to the method provided by the invention, the immunogenicity of the high-homology antigen can be obviously improved.

This invention discloses an immunohydrogel for in situ treatment of bladder cancer and its preparation method. The immunohydrogel material provided by this invention comprises dopamine-modified oxidized mannodular glucan, thiolated hyaluronic acid, BCG, and arginine. After instillation, it forms an adhesive three-dimensional network structure in situ within the bladder, transforming the traditional "multiple instillation" model into a "single instillation, long-term effect" model. Simultaneously, the arginine in the system locally generates NO, enhancing T cell function through metabolism. The glucan component synergistically activates innate immunity such as dendritic cells, thereby systematically enhancing the BCG-triggered anti-tumor immune response, improving efficacy, and inducing long-term immune memory. This invention fundamentally improves the practicality of BCG therapy, significantly reducing the risk of tumor recurrence while decreasing the frequency of instillation and the dosage of BCG, providing a new generation of instillation immunotherapy strategy for the postoperative management of NMIBC.

The invention discloses long-chain non-coding RNA found from plasma of a natural tuberculosis resister and application of the long-chain non-coding RNA, and belongs to the technical field of molecular biology. The long-chain non-coding RNA provided by the invention can be used as a plasma marker to prompt the susceptibility of an individual to tuberculosis. The invention also provides a method for delivering the long-chain non-coding RNA to the mononuclear-macrophage by using the lipid nanoparticles, so that the immune response level and the immune clearance ability of the mononuclear-macrophage for resisting Mtb infection are enhanced. Therefore, the achievement of the invention provides a thought for developing immunological enhancement medicaments for preventing and treating tuberculosis, and particularly has wide prospects in the aspects of preparation and clinical application of novel BCG vaccine immunologic adjuvants and the like.